Table 2.
Characteristics and comparison of the two study populations, excluding HRV and hMPV.
| RVPP (n = 156) | SV (n = 112) | p-Value | |
|---|---|---|---|
| Age (%) | 0.22 | ||
| 2–23 months | 92 (59) | 74 (66) | |
| 2–5 years | 39 (25) | 24 (21) | |
| 6–10 years | 10 (6) | 5 (4) | |
| 11–18 years | 15 (10) | 9 (8) | |
| Male sex (%) | 80 (51) | 56 (50) | 0.78 |
| Race/ethnicity (%) | 0.65 | ||
| White | 98 (65) | 68 (64) | |
| Black | 30 (20) | 16 (15) | |
| Hispanic | 10 (7) | 12 (11) | |
| Other | 12 (8) | 10 (9) | |
| Comorbidity (%) | |||
| Total number, mean (range) | 2.2 (0–8) | 2.7 (0–8) | 0.04 |
| Any comorbidity | 137 (88) | 95 (85) | 0.47 |
| Respiratory virus(es) isolated (%) | |||
| Adenovirus | 33 (21) | 12 (11) | 0.022 |
| Influenza A | 14 (9) | 6 (5) | 0.25 |
| Influenza B | 10 (6) | 3 (3) | 0.1 |
| Parainfluenza 1 | 3 (2) | 11 (10) | 0.011 |
| Parainfluenza 2 | 6 (4) | 3 (3) | 0.59 |
| Parainfluenza 3 | 23 (15) | 8 (7) | 0.047 |
| Respiratory syncytial virus | 77 (49) | 62 (55) | 0.34 |
| Medications | |||
| Received antivirals | |||
| Oseltamivir | 16 (10) | 13 (12) | 0.76 |
| Ribavirin | 1 (1) | 6 (5) | 0.035 |
| Received antibacterials | |||
| Vancomycin | 31 (20) | 38 (34) | 0.13 |
| Ceftriaxone/Cefotaxime | 26 (17) | 20 (18) | 0.78 |
| Penicillin/Ampicillin | 2 (1) | 1 (1) | 0.76 |
| Clinical course and management | |||
| Required mechanical ventilation (%) | 69 (44) | 44 (39) | 0.42 |
| Median length of hospital stay (LOS) *, (range) | 3.6 (0.1–133.0) | 3.9 (0.7–304.3) | 0.05 |
| LOS in log scale, mean (SD) | 1.40 (0.98) | 1.65 (1.23) | 0.062 |
| Readmission within 14 days (%) | 7 (4) | 7 (6) | 0.53 |
| Mortality (%) | 2 (1) | 10 (9) | 0.008 |
| Hospital charges | |||
| Median, dollars (range) | 33,796 (2953–4,015,593) | 27,373 (1099–4,068,499) | |
| Charges in log scale, mean (SD) | 10.57 (1.16) | 10.74 (1.58) | 0.29 |
SD: standard deviation; *, days.